Cite
HARVARD Citation
Wu, X. et al. (n.d.). 998TiPPamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China. Annals of oncology. p. . [Online].